BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer

Cancer Immunity

Volumn 13, Issue 1, 2013, Pages

  Link, Petra A ^a   Zhang, Wa ^a,b   Odunsi, Kunle ^a   Karpf, Adam R ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

BORIS; CTCF; DNA methylation; Epigenetics; Ovarian cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CHROMOSOME PROTEIN; DNA; ISOPROTEIN; MESSENGER RNA; PROTEIN BORIS; PROTEIN CTCFL; TRANSCRIPTION FACTOR CTCF; TRICHOSTATIN A; UNCLASSIFIED DRUG; CTCFL PROTEIN, HUMAN; DNA BINDING PROTEIN;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETIC REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; BORIS; CTCF; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LONG INTERSPERSED REPEAT; MALE; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY; OVARY CANCER; OVARY TUMOR; PATHOLOGY; TESTIS;

BORIS; CTCF; DNA METHYLATION; EPIGENETICS; OVARIAN CANCER;

DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MALE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PROTEIN ISOFORMS; RNA, MESSENGER; TESTIS;

EID: 84873158945     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-2529.(PMID: 15590954)
2. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y. The distal fallopian tube: A new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19: 3-9.(PMID: 17218844)
3. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/ testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-625. (PMID: 16034368)
4. Scudellari M. A ballsy search for cancer targets. Nat Med 2011; 17: 916-918.(PMID: 21818078)
5. D'Arcy V, Pore N, Docquier F, Abdulla ZK, Chernukhin I, Kita GX, Rai S, Smart M, Farrar D, Pack S, Lobanenkov V, Klenova E. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer 2008; 98: 571-579.(PMID: 18195709)
6. Risinger JI, Chandramouli GV, Maxwell GL, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS, Murphy SK, Ber-chuck A, Lobanenkov V, Barrett JC. Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res 2007; 13: 1713-1719.(PMID: 17363524)
7. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 2007; 7: 21.(PMID: 18095639)
8. Renaud S, Loukinov D, Alberti L, Vostrov A, Kwon YW, Bosman FT, Lobanenkov V, Benhattar J. BORIS/CTCFL-mediated tran-scriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic Acids Res 2011; 39: 862-873.(PMID: 20876690)
9. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 2005; 65: 7763-7774.(PMID: 16140944)
10. Woloszynska-Read A, James SR, Song C, Jin B, Odunsi K, Karpf AR. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer Immun 2010; 10: 6.(PMID: 20649179)
11. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H 3rd, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 2005; 65: 7751-7762.(PMID: 16140943)
12. Kholmanskikh O, Loriot A, Brasseur F, De Plaen E, De Smet C. Expression of BORIS in melanoma: Lack of association with MAGE-A1 activation. Int J Cancer 2008; 122: 777-784.(PMID: 17957795)
13. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-5337.(PMID: 19723653)
14. Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG. DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther 2008; 15: 61-64.(PMID: 17972923)
15. Mkrtichyan M, Ghochikyan A, Davtyan H, Movsesyan N, Loukinov D, Lobanenkov V, Cribbs DH, Laust AK, Nelson EL, Agadjanyan MG. Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol 2011; 270: 188-197.(PMID: 21641588)
16. Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N, Ichim TE, Cribbs DH, Lobanenkov VV, Agad-janyan MG. Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol 2007; 178: 566-573.(PMID: 17182597)
17. Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Cher-nukhin I, Mannan P, Larsson E, Kanduri C, Vostrov AA, Cui H, Niemitz EL, Rasko JE, Docquier FM, Kistler M, Breen JJ, Zhuang Z, Quitschke WW, Renkawitz R, Klenova EM, Feinberg AP, Ohlsson R, Morse HC 3rd, Lobanenkov VV. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A 2002; 99: 6806-6811.(PMID: 12011441)
18. Klenova EM, Morse HC 3rd, Ohlsson R, Lobanenkov VV. The novel BORIS + CTCF gene family is uniquely involved in the epi-genetics of normal biology and cancer. Semin Cancer Biol 2002; 12: 399-414.(PMID: 12191639)
19. Hore TA, Deakin JE, Marshall Graves JA. The evolution of epigene-tic regulators CTCF and BORIS/CTCFL in amniotes. PLoS Genet 2008; 4: e1000169.(PMID: 18769711)
20. Fiorentino FP, Giordano A. The tumor suppressor role of CTCF. J Cell Physiol 2012; 227: 479-492.(PMID: 21465478)
21. Pugacheva EM, Suzuki T, Pack SD, Kosaka-Suzuki N, Yoon J, Vostrov AA, Barsov E, Strunnikov AV, Morse HC 3rd, Loukinov D, Lobanenkov V. The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS One 2010; 5: e13872. (PMID: 21079786)
22. Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdul-laev Z, Loukinov D, Benhattar J, Lobanenkov V. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res 2007; 35: 7372-7388.(PMID: 17962299)
23. Rosa-Garrido M, Ceballos L, Alonso-Lecue P, Abraira C, Delgado MD, Gandarillas A. A cell cycle role for the epigenetic factor CTCF-L/BORIS. PLoS One 2012; 7: e39371.(PMID: 22724006)
24. Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley LA, Odunsi K, Karpf AR. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: Association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 2011; 17: 2170-2178.(PMID: 21296871)
25. de Necochea-Campion R, Ghochikyan A, Josephs SF, Zacharias S, Woods E, Karimi-Busheri F, Alexandrescu DT, Chen CS, Agadjan-yan MG, Carrier E. Expression of the epigenetic factor BORIS (CTCFL) in the human genome. J Transl Med 2011; 9: 213.(PMID: 22168535)
26. Ahmed AA, Becker CM, Bast RC Jr. The origin of ovarian cancer. BJOG 2012; 119: 134-136.(PMID: 22168761)
27. Akers SN, Odunsi K, Karpf AR. Regulation of cancer germline antigen gene expression: Implications for cancer immunotherapy. Future Oncol 2010; 6: 717-732.(PMID: 20465387)
28. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.(PMID: 21720365)
29. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.(PMID: 9916800)
30. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002; 21: 5496-5503.(PMID: 12154410)
31. Karpf AR. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 2006; 1: 116-120.(PMID: 17786175)
32. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methyla-tion status in ovarian cancer. Clin Cancer Res 2008; 14: 3283-3290.(PMID: 18519754)